Brought to you by 
Homology Medicines nets $135.1mm via FOPO
20 Aug 2019
Executive Summary
Genetic medicines developer Homology Medicines Inc. netted $135.1mm in its follow-on public offering of 6.39mm common shares (including full exercise of the overallotment) at $22.50. The company will use the proceeds to move its lead gene therapy program HMI102 for adults with phenylketonuria through a Phase I/II trial; to advance both HMI202 for metachromatic leukodystrophy and HMI103 for pediatric PKU through IND-enabling studies and possibly into the clinic; to move other pipeline programs through preclinical development; to further expand its intellectual property portfolio; and to potentially expand its manufacturing capacity.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Homology Medicines nets $135.1mm via FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice